ATEC:NSD-Alphatec Holdings Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 14.36

Change

+0.32 (+2.28)%

Market Cap

USD 1.41B

Volume

1.13M

Avg Analyst Target

USD 21.63 (+50.59%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; squadron lateral retractor designed to maximize patient outcomes; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System designed to improve surgical efficiency without compromising accuracy. It also provides Invictus Modular Fixation Systems designed to increase adaptability with the power of screw modularity; OsseoScrew system to restore the integrity of the spinal column; Arsenal spinal fixation system, a comprehensive thoracolumbar fixation platform to fix a range of degenerative to deformity pathologies and surgical procedures; Aspida Anterior Lumbar Plating System, a fixation system for anterior lumbar interbody fusion; AMP Anti-Migration Plate; solanas posterior cervico/thoracic fixation system and avalon occipital plate; OCT Spinal Fixation System; trestle luxe anterior cervical plate system; and Insignia Anterior Cervical Plate System. In addition, the company offers IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Interbody Implants; and biologics consisting of Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier. Further, it develops EOS imaging products. It sells its products through a network of independent distributors and direct sales representatives in the United States. The company was founded in 1990 and is based in Carlsbad, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-22 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology Inc

+7.46 (+1.05%)

USD56.12B 80.83 55.99
PODD Insulet Corporation

-5.32 (-1.81%)

USD20.18B 2,208.27 247.34
ABMD Abiomed Inc

+3.97 (+1.15%)

USD15.66B 102.01 53.06
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
BRKR Bruker Corporation

+1.24 (+1.51%)

USD12.41B 52.96 28.22
TNDM Tandem Diabetes Care Inc

+0.54 (+0.44%)

USD7.78B 1,198.93 239.94
SWAV ShockWave Medical Inc

+8.48 (+3.94%)

USD7.57B N/A N/A
IART Integra LifeSciences Holdings ..

+1.64 (+2.36%)

USD5.91B 28.79 19.16
INMD InMode Ltd

+8.14 (+5.45%)

USD5.71B 49.98 40.15
LIVN LivaNova PLC

+0.71 (+0.87%)

USD4.33B 77.40 N/A

ETFs Containing ATEC

Symbol Name Weight Mer Price(Change) Market Cap
JFWD Jacob Funds Inc. - Jacob .. 0.00 % 0.00 %

+0.45 (+2.22%)

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.10% 36% F 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.10% 36% F 37% F
Trailing 12 Months  
Capital Gain 131.99% 75% C 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 131.99% 75% C 88% B+
Trailing 5 Years  
Capital Gain 66.40% 66% D 62% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 66.40% 66% D 59% F
Average Annual (5 Year Horizon)  
Capital Gain 74.09% 86% B 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 74.09% 86% B 90% A-
Risk Return Profile  
Volatility (Standard Deviation) 111.57% 24% F 14% F
Risk Adjusted Return 66.41% 86% B 81% B-
Market Capitalization 1.41B 81% B- 71% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 6.50 34% F 22% F
Price / Cash Flow Ratio -30.29 75% C 84% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -74.10% 29% F 23% F
Return on Invested Capital -34.29% 37% F 22% F
Return on Assets -14.15% 41% F 24% F
Debt to Equity Ratio 29.28% 55% F 51% F
Technical Ratios  
Short Ratio 4.09 48% F 41% F
Short Percent 8.28% 20% F 22% F
Beta 1.58 35% F 25% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector